Sahebarao P Mahadik
Overview
Explore the profile of Sahebarao P Mahadik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pillai A, Kale A, Joshi S, Naphade N, V K Raju M, Nasrallah H, et al.
Int J Neuropsychopharmacol
. 2009 Nov;
13(4):535-9.
PMID: 19941699
Brain-derived neurotrophic factor (BDNF), which plays an important role in neurodevelopmental plasticity and cognitive performance, has been implicated in neuropsychopathology of schizophrenia. We examined the levels of both cerebrospinal fluid...
2.
Kale A, Joshi S, Pillai A, Naphade N, Raju M, Nasrallah H, et al.
Schizophr Res
. 2009 Aug;
115(2-3):209-14.
PMID: 19713082
Impaired expression and function of several major neurotrophic factors such as nerve growth factor (NGF) has been proposed to contribute to the neurodevelopmental pathology of schizophrenia. However, the evidence in...
3.
Lieberman J, Bymaster F, Meltzer H, Deutch A, Duncan G, Marx C, et al.
Pharmacol Rev
. 2008 Oct;
60(3):358-403.
PMID: 18922967
Various lines of evidence indicate the presence of progressive pathophysiological processes occurring within the brains of patients with schizophrenia. By modulating chemical neurotransmission, antipsychotic drugs may influence a variety of...
4.
Pillai A, Veeranan-Karmegam R, Dhandapani K, Mahadik S
J Neurochem
. 2008 Sep;
107(4):941-51.
PMID: 18786174
The role of brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology as well as treatment outcome of schizophrenia. Rodent studies indicate that several antipsychotic drugs have time-dependent (and...
5.
Pillai A, Mahadik S
Schizophr Res
. 2008 Jan;
100(1-3):325-33.
PMID: 18187310
Heterozygous reeler mouse has been used as an animal model for schizophrenia based on several neuropathological and behavioral abnormalities homologous to schizophrenia. Since some of these abnormalities are primarily associated...
6.
Kale A, Joshi S, Naphade N, Sapkale S, V K Raju M, Pillai A, et al.
Schizophr Res
. 2007 Nov;
98(1-3):295-301.
PMID: 17997280
Variable levels of essential polyunsaturated fatty acids (EPUFAs) reported in schizophrenia are likely due to differences in age, sex, ethnicity, diet, life style and treatments. The present study examined the...
7.
Pillai A, Dhandapani K, Pillai B, Terry Jr A, Mahadik S
Neuropsychopharmacology
. 2007 Sep;
33(8):1942-51.
PMID: 17805306
Functional alterations in the neurotrophin, brain-derived neurotrophic factor (BDNF) have recently been implicated in the pathophysiology of schizophrenia. Furthermore, animal studies have indicated that several antipsychotic drugs have time-dependent (and...
8.
Terry Jr A, Mahadik S
J Pharmacol Exp Ther
. 2006 Sep;
320(3):961-8.
PMID: 16966470
Although cognitive dysfunction is considered one of the more debilitating symptoms of schizophrenia, there is a fundamental gap in our knowledge of how the primary pharmacologic treatments of this disease,...
9.
Pillai A, Mahadik S
J Neurochem
. 2006 Aug;
98(5):1411-22.
PMID: 16923156
Compared with first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs) seem to be neuroprotective and trigger neuroplasticity. Because neuroplasticity is regulated by a variety of neurotrophic factors we studied differential effects of...
10.
Pillai A, Mahadik S
Schizophr Res
. 2006 Jul;
87(1-3):48-59.
PMID: 16859894
Compared to first-generation antipsychotics (FGAs) such as haloperidol, second-generation antipsychotics (SGAs) such as olanzapine are found superior to improve cognitive performance and reduce negative symptoms with no extrapyramidal symptoms (EPS)....